Influenza vaccination perception and coverage among patients with malignant disease |
| |
| Affiliation: | 1. Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria;2. Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria;3. Clinical Division of Hematology and Hemostasis, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria;4. Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria;1. Department of Global Health and Development, London School of Hygiene & Tropical Medicine, Tavistock Place, London WC1H 9SH, UK;1. Research Institute for Complex Issues of Cardiovascular Diseases under the Siberian Branch of the Russian Academy of Medical Sciences, Kemerovo, 650002, Sosnovy Bulvar 6, Russia;2. Department of Cardiology and Cardiovascular Surgery, Kemerovo State Medical Academy, Kemerovo, 650002, Sosnovy Bulvar 6, Russia;3. Kemerovo Cardiological Centre, Kemerovo, 650002, Sosnovy Bulvar 6, Russia;4. Department of Epidemiology, Kemerovo State Medical Academy, Kemerovo, 650029, Voroshilova Street 22a, Russia;5. Central Research Laboratory, Kemerovo State Medical Academy, Kemerovo, 650029, Voroshilova Street 22a, Russia;1. Department of Hematology and Hematopoietic Cell Transplantation and;2. Department of Pathology, City of Hope, Duarte, CA; and;3. Division of Blood and Marrow Transplantation, University of California San Diego Moores Cancer Center, La Jolla, CA;1. Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK;2. High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK;3. Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK;4. Structural Biology Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK;5. Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK;6. Safety, Health & Sustainability, The Francis Crick Institute, London NW1 1AT, UK;7. Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK;8. Metabolomics Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK;9. Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK;10. Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK;11. Neurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK;12. Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK;13. RNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK;14. Retroviral Immunology Laboratory, The Francis Crick Institute, London NW1 1AT, UK;15. Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK;p. Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK;q. Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK;r. Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK;s. Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK;t. Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK;u. Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK;v. Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK;w. University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, UK;x. Translational Cancer Biochemistry Laboratory, Institute of Cancer Research, London, UK;y. Melanoma and Kidney Cancer Team, Institute of Cancer Research, London, UK;z. Division of Medicine, University College London, London, UK;11. University College London Cancer Institute, London, UK;12. UCL Queen Square Institute of Neurology, London, UK |
| |
| Abstract: | BackgroundPatients with malignancies are at increased risk of serious influenza related complications with higher rates of hospitalization and mortality than healthy cohorts. Although annual vaccination against influenza infection is recommended, vaccination rates among cancer patients are apparently low. The reasons for the low compliance to influenza vaccine and the influenza vaccination rate among Austrian cancer patients have not been studied in detail yet.Patients and methodsFrom July 1, 2013 to October 31, 2013, 444 patients treated in the outpatient departments of the Clinical Division of Oncology and the Clinical Division of Haematology and Haemostaseology of the General Hospital Vienna participated in a survey on different aspects of influenza vaccination.ResultsIn total, only 80 out of 444 patients (18%) had received influenza vaccination in the previous year. The influenza vaccination rate was higher amongst patients with haematological malignancies (22%) compared to patients with solid tumours (13%). Higher age was significantly associated with a higher probability for being vaccinated. Collecting information about influenza vaccination primarily from media or the internet was not significantly associated with influenza vaccination status. Information through a medical consultation or a recommendation by the attending physician resulted in significant higher influenza vaccination coverage rates. Only 199 out of the 444 patients (44.8%) were informed by a physician about influenza vaccination and only 18 out of 337 patients (5.3%) with a diagnosis of a malignant disease were informed by their treating oncologist. The main reasons for influenza vaccination denial were concerns about interaction with the malignant disease and potential side-effects.ConclusionInformation about influenza vaccination during a medical consultation and a clear recommendation by the attending physician are highly predictive for acceptance of influenza vaccination. Increased awareness among physicians, especially oncologists is of utmost importance to effectively improve IVR in patients with malignant disease. |
| |
| Keywords: | Influenza Vaccination Predictors Compliance Malignant disease Chemotherapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
